SLC5A2 and type 2 diabetes mellitus: Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, caused an increase in EPO and ERFE and a fall in hepcidin when given to obese patients with T2DM for 12 weeks [113].